**Supplementary Table 3: Cost-effectiveness outcomes for the base-case CEA analysis and sensitivity analyses – Complete case analyses**

|  |  |  |  |  |  |  |  |
| --- | --- | --- | --- | --- | --- | --- | --- |
|  | **Mean costs (95% CI)** |  | **Mean effects (95% CI)** |  |  |  | **Probability MgSO4 is** |
| **Analysis**1 | **MgSO4 (GBP)** | **Placebo (GBP)** | **Difference (GBP)** |  | **MgSO4 (GBP)** | **Placebo (GBP)** | **Difference (GBP)** |  | **ICER (GBP)** |  | **More effective\* (%)** | **Less costly\* (%)** | **Cost-effective\*****(%)2** | **Cost-effective\*****(%)3** |
| Base-case | 908(764, 1052) | 863(752, 975) | 45(-138, 227) |  | 4.72(4.54, 4.90) | 4.95(4.78, 5.13) | 0.24§(-0.02, 0.49) |  | 189 |  | 88.00 | 36.60 | 75.10 | 85.50 |
| Higher level inpatient care valued using NHS cost for paediatric high dependency care (GBP 886) | 813(708, 918) | 794(718, 871) | 18(-111, 148) |  | 4.72(4.54, 4.90) | 4.95(4.78, 5.13) | 0.24(-0.01, 0.49) |  | 78 |  | 89.50 | 41.90 | 81.50 | 87.80 |
| Higher level inpatient care valued using NHS cost for paediatric intensive care (GBP 2225) | 1027(826, 1227) | 950(790, 1109) | 77(-179, 333) |  | 4.72(4.54, 4.90) | 4.95(4.78, 5.13) | 0.24(-0.01, 0.49) |  | 327 |  | 89.20 | 32.60 | 68.30 | 85.90 |
| Exact LOS used | 783(649, 917) | 753(651, 855) | 30(-139, 198) |  | 4.72(4.54, 4.90) | 4.95(4.78, 5.13) | 0.24(-0.01, 0.49) |  | 126 |  | 89.50 | 42.60 | 81.00 | 87.50 |
| LOS rounded up to full days | 1019(867, 1172) | 964(844, 1084) | 56(-139,250) |  | 4.72(4.54, 4.90) | 4.95(4.78, 5.13) | 0.24(-0.01, 0.49) |  |  |  | 88.90 | 35.00 | 74.70 | 86.70 |
| NHS Reference costs used to value A&E visit | 876(732, 1020) | 831(719, 942) | 45(-136, 227) |  | 4.72(4.54, 4.90) | 4.95(4.78, 5.13) | 0.24(-0.01, 0.49) |  | 193 |  | 87.70 | 36.70 | 76.50 | 85.40 |
| NHS Reference costs used to value stay on GM ward | 943(797, 1090) | 900(787, 1013) | 43(-142, 228) |  | 4.72(4.54, 4.90) | 4.95(4.78, 5.13) | 0.24(-0.01, 0.49) |  | 184 |  | 90.30 | 38.50 | 78.10 | 88.70 |
| § The difference in effects was inverted, i.e. negative values were given a positive sign, to reflect the fact that a decrement in ASS score is synonymous with a positive health effect1Complete case analysis included placebo N=244; MgSO4 N=2282 MgSO4 was considered to be “cost-effective” if it had positive net benefit at a GBP 1000 cost-effectiveness threshold3 MgSO4 was considered to be “cost-effective” if it had positive net benefit at a GBP 5000 cost-effectiveness threshold\* Based on 1000 bootstrap replicates of the datasetCI, confidence interval; ICER, incremental cost-effectiveness ratio; LOS, length of stay. |  |  |